CAR-T cell therapy tisagenlecleucel (Kymriah) has been funded by the federal government for paediatric and young adult patients up to the age of 25 with B-cell precursor ALL. The funding, through public hospitals via the National Health Reform Agreement, follows long-anticipated approval by the Medical Services Advisory Committee (MSAC) for its use in young patients with ...
CAR-T Cell therapy funded for children and young adults with ALL
By David Rowley
16 Apr 2019